Employees: 5,715
Size Guizhou Bailing Group Pharmaceutical (002424.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $755M, the 2710th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥3.88 on 18 Nov 2026.
Performance Over six months the shares fell 20.5%, against -8.5% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 19 in its peer set.
Growth Revenue fell 25.2% over the last twelve months (peer median +3.5%); the operating margin is 2.5% (peer median 9.6%).
Valuation It trades at 2.5× enterprise value to sales against a peer median of 2.6× (9th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.9 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.36B | CN¥3.02B | CN¥3.79B | CN¥4.21B | CN¥3.49B |
| Revenue growth | — | -20% | -10% | +21% | — |
| Gross profit | CN¥973M | CN¥1.37B | CN¥2.14B | CN¥2.25B | CN¥2.04B |
| EBITDA | n/a | CN¥223M | CN¥179M | -CN¥293M | CN¥326M |
| Net income | -CN¥129M | -CN¥104M | CN¥33.6M | -CN¥415M | CN¥138M |
| Free cash flow | CN¥132M | CN¥635M | -CN¥24.2M | CN¥30.4M | CN¥395M |
| Capital expenditure | CN¥113M | CN¥125M | CN¥42.0M | CN¥104M | CN¥68.5M |
| Total debt | CN¥1.06B | CN¥1.29B | CN¥1.89B | CN¥1.78B | CN¥1.70B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002424.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.3% | -3.7% | 4th lowest of 19 |
| 6-month return | -20.5% | -8.5% | 8th lowest of 19 |
| Distance from 52-week high | -37.9% | -32.6% | 6th lowest of 19 |
| Revenue growth (TTM) | -25.2% | +3.5% | 2nd lowest of 19 |
| Operating margin | 2.5% | 9.6% | 5th lowest of 19 |
| EV / Sales | 2.5× | 2.6× | 9th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 13.5% | 0.3% | 3rd most demanding of 12 |
| Growth delivered (Del g) | -0.2% | +1.9% | 4th lowest of 12 |
| Hurdle (Req g minus delivered) | +13.7 pp | -3.1 pp | 3rd most demanding of 12 |
| ROIC minus cost of capital | -1.9 pp | +0.2 pp | 6th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | 2.5× | 13.5% | -0.2% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | 5.3× | 9.4% | -1.4% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | 28.6× | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | 1.4× | -2.1% | 0.0% |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | 2.4× | 0.3% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | 16.7× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | 0.9× | -3.8% | -0.8% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 1.8× | -2.0% | +26.1% |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 1.1× | -11.8% | +1.9% |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | 6.7× | 33.9% | +10.1% |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | 0.3× | n/a | n/a |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 1.6× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | 3.1× | -2.5% | +2.6% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 3.8× | 5.9% | +11.3% |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | 16.1× | 42.7% | -0.9% |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 3.9× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 2.6× | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 1.8× | 6.6% | +17.7% |